UCB FIRST LOOK: $ 680m divestiture of mature assets in China
UCB divests its mature product portfolio in neurology (Keppra, Vimpat, Neupro) and allergy (Zyrtec, Xyzal) in China to CBC Group and Mubadala Investment Company for $ 680m. The divestment will create a new leading neurology company that operates at scale in China, as UCB's strategy for the country evolves toward a stronger focus on innovation and partnerships. We deem the transaction as a logical route forward in China at a seemingly fair price and reiterate our € 161 TP and Hold rating.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.